NASDAQ:PACBPacific Biosciences of California Stock Price, Forecast & News

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PACB stock has increased by 3.2% and is now trading at $3.55. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacific Biosciences of California.

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Pacific Biosciences of California.

Pacific Biosciences of California (NASDAQ:PACB) posted its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05. The biotechnology company had revenue of $15.60 million for the quarter, compared to analysts' expectations of $20.10 million. Pacific Biosciences of California had a negative return on equity of 131.21% and a negative net margin of 58.35%. View Pacific Biosciences of California's earnings history.

3 analysts have issued 12-month target prices for Pacific Biosciences of California's stock. Their forecasts range from $5.00 to $7.00. On average, they anticipate Pacific Biosciences of California's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 69.0% from the stock's current price. View analysts' price targets for Pacific Biosciences of California.

News headlines about PACB stock have trended very positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacific Biosciences of California earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutPacific Biosciences of California.

Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), Novavax (NVAX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Advanced Micro Devices (AMD), ImmunoGen (IMGN), Alibaba Group (BABA), BioCryst Pharmaceuticals (BCRX), FireEye (FEYE) and Micron Technology (MU).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.33%), Capital International Investors (4.41%), Capital World Investors (3.53%), Water Island Capital LLC (3.53%), Weiss Multi Strategy Advisers LLC (2.76%) and State Street Corp (2.33%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View institutional ownership trends for Pacific Biosciences of California.

PACB stock was sold by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Healthcare of Ontario Pension Plan Trust Fund, Morgan Stanley, Public Sector Pension Investment Board, UBS Group AG, ArrowMark Colorado Holdings LLC, Alliancebernstein L.P., and BNP Paribas Arbitrage SA. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Michael Hunkapiller, and Susan K Barnes. View insider buying and selling activity for Pacific Biosciences of California.

PACB stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Weiss Multi Strategy Advisers LLC, Camber Capital Management LP, Assenagon Asset Management S.A., Capital International Investors, BlackRock Inc., JPMorgan Chase & Co., and Water Island Capital LLC. View insider buying and selling activity for Pacific Biosciences of California.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $3.55.

Pacific Biosciences of California has a market capitalization of $546.95 million and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.

The official website for Pacific Biosciences of California is www.pacb.com.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]